Month: May 2022

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

May 17, 2022, 07:30 ET Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® – Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a …

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update Read More »

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

May 12, 2022, 08:00 ET CRANBURY, N.J., May 12, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced  that it has entered into a securities purchase agreement with institutional investors …

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock Read More »

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

May 11, 2022, 09:02 ET CRANBURY, N.J., May 11, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its …

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022 Read More »

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

May 02, 2022, 13:02 ET Posters highlight Palatin’s ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J., May 2, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at …

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference Read More »

Scroll to Top